CA-C3-AI
16.2.2021 22:29:13 CET | Business Wire | Press release
C3 AI (NYSE:AI), a leading enterprise AI software provider, today announced the release of major enhancements to its enterprise AI application development platform and AI applications designed to further accelerate digital transformation. Over the past decade, C3 AI has invested continuously in the C3 AI® Suite, its open, secure, and multi-cloud enterprise AI platform that leverages a model-driven architecture, enabling end-to-end enterprise AI including data integration, model development, MLOps, application development, and model governance and maintenance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210216006166/en/
The latest release – Version 7.17 – provides new capabilities to track and manage full lineage from data sources to application entities. In addition, the latest release includes new composable machine learning (ML) pipelines for data scientists; enhancements to C3 AI CRM, C3 AI Anti-Money Laundering, C3 AI Energy Management, C3 AI Production Schedule Optimization, and C3 AI Reliability applications; and a new enterprise AI application for the oil and gas industry, C3 AI Well Development Optimization.
“Today’s release introduces even more market-leading features for developers, data scientists, and data engineers, while bringing unparalleled speed to the development of enterprise AI applications,” said C3 AI President and Chief Product Officer Houman Behzadi. “We continue to invest significantly in our enterprise AI platform, wide range of developer tools, and configurable enterprise AI applications to enable a richer and more cohesive developer and user experience to accelerate AI adoption.”
The latest platform enhancements and features available with the C3 AI Suite include:
- Comprehensive data, feature, and model lineage: Improvements to enterprise AI application development tools include a new comprehensive data, feature, and model lineage component that enables developers and end users to understand the lineage of their application and AI/ML results.
- Enhanced time series feature generation: The latest release significantly accelerates feature engineering and model development. Enhancements enable faster feature parameterization, more comprehensive statistical transformations, and improved feature selection for use in C3 AI ML Pipelines.
- New composable ML pipelines: Expanding the ever-growing library of C3 AI ML Pipelines, the latest release includes four new pipelines to accelerate model development, including a deep learning pipe for forecasting and a linear quantile regression pipe for probabilistic predictions. C3 AI ML Pipelines also deliver improved model interpretability support with the addition of SHAP (Shapley Additive Explanations) to the available explainability frameworks.
- Multi-cloud Kubernetes service: As part of the ongoing Kubernetes/OpenShift standardization, the latest release supports the Kubernetes service on all clouds.
- New prebuilt data connectors: Performance and scalability improvements to C3 AI’s Virtual Data Lake framework include connectors to Snowflake, Spark/Databricks, S3, Microsoft Power BI, Azure Data Lake, and Microsoft Dynamics 365 – further expanding the library of prebuilt data connectors on the C3 AI Suite. The new connectors help accelerate data integration and allow engineers to create a virtual data image or ingest data directly into the C3 AI Suite.
- Enhancements to enterprise object models: New additions and enhancements to C3 AI’s suite of prebuilt enterprise object models further accelerate development of AI applications. Cross-industry object models provide functional capabilities, including energy management, equipment and process reliability, fraud detection, inventory optimization, and manufacturing yield optimization. In addition, C3 AI also offers industry-specific object models for manufacturing, financial services, oil and gas, utilities, and defense.
C3 AI also continues to invest in its growing portfolio of enterprise AI applications. Notable enhancements include:
- C3 AI CRM delivers a new AI-based precision revenue forecasting and opportunity scoring feature leveraging both data in traditional CRM systems and external feeds (e.g., financial data, news, commodity prices).
- C3 AI Reliability enhancements include a new module – C3 AI Diagram Parsing – to automatically generate digital twins and object models from piping and instrumentation diagrams (P&IDs). C3 AI Diagram Parsing uses machine vision and natural language processing to parse P&IDs to generate machine-readable asset hierarchies and sensor-to-asset mappings.
- C3 AI Inventory Optimization enhancements include what-if scenario modeling capabilities for inventory analysts to account for the ever-changing dynamics of globally distributed supply chains and optimize for the best operating outcomes.
- C3 AI Production Schedule Optimization enhancements include a new user interface, enhancements to the object model, and additional composable ML pipelines. Modifications to the user interface enable end users to more easily generate, review, and act on AI-based demand forecasts and order line recommendations. The newly available demand planning and scheduling data models and ML pipelines help accelerate model development and deployment for data science teams.
- C3 AI Well Development Optimization is a new oil and gas application that optimizes upstream drilling costs and mitigates non-productive time risks such as stuck pipe, lost circulation, and drilling recovery. The application provides the foundational data model for AI-enabled well development applications, as well as for upstream oil and gas operators to plan and execute drilling operations.
For more information about this new release, please contact sales@c3.ai .
About C3.ai, Inc.
C3.ai, Inc. (NYSE:AI) is a leading provider of enterprise AI software for accelerating digital transformation. C3 AI delivers a family of fully integrated products: C3 AI® Suite, an end-to-end platform for developing, deploying, and operating large-scale AI applications; C3 AI Applications, a portfolio of industry-specific SaaS AI applications; C3 AI CRM, a suite of industry-specific CRM applications designed for AI and machine learning; and C3 AI Ex Machina, a no-code AI solution to apply data science to everyday business problems. The core of the C3 AI offering is an open, model-driven AI architecture that dramatically simplifies data science and application development. Learn more at: www.c3.ai
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216006166/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 14:40:00 CEST | Press release
Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa
ParaScript Acquired by Stakk to Create a Global Digital Trust Platform Focused on Combating Fraud24.9.2026 14:30:00 CEST | Press release
ParaScript’s AI-powered document intelligence technology integrates with Stakk’s SaaS platform to provide regulated organizations with a stronger defense against AI-driven digital identity fraud.Complementary technologies establish digital trust by continuously assessing identity, documents, behavior and context, making explainable decisions in milliseconds.Combined businesses serve more than 300 enterprise customers and processes more than 110 billion digital interactions annually across the U.S., Europe, the Middle East and Australia. ParaScript, an Al-powered document processing company, today announced that Stakk Limited (ASX: SKK) (“Stakk”), a company publicly traded on the Australian Stock Exchange (ASX), has successfully completed its US$63 million (A$88.7 million) acquisition of ParaScript, LLC and ParaScript Management, Inc. (“ParaScript”), creating a scaled and profitable AI-native digital trust platform. Stakk acquired ParaScript for its industry-leading AI-powered document
SLB Awarded Four Multi-Year Integrated Well Construction Contracts by Aramco24.9.2026 14:04:00 CEST | Press release
Awards expand deployment of SLB's integrated well construction model across Saudi Arabia’s oil and gas reservoirs Global energy technology company SLB (NYSE: SLB) today announced it has been awarded four integrated well construction contracts by Aramco to support oil and gas development across the Kingdom of Saudi Arabia. Under the contracts, SLB will manage end-to-end well construction services, delivering more than 450 wells in the three-year term, with an optional extension of up to two years. "Delivering hundreds of wells across a multi-year program and in multiple operating environments requires an integrated model that connects planning, execution, and digital workflows to set new industry performance benchmarks,” said Steve Gassen, executive vice president of Geographies for SLB. “Awarding SLB these advanced well construction programs at scale reflects Aramco’s confidence in our integrated model and capabilities." SLB's integrated well construction model brings together every as
Sahajanand Medical Technologies Receives EU MDR Certification for Supraflex Cruz and Product Family, Reinforcing Global Compliance and Patient Safety24.9.2026 14:03:00 CEST | Press release
Sahajanand Medical Technologies Limited (SMT), a leading global manufacturer of cardiovascular medical devices, today announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family. SMT is a leading player in India’s drug-eluting stent market and ranks among the top five companies in key European markets, including Germany, Spain and Poland. The certification follows the conformity assessment process established under EU MDR 2017/745 including assessment of SMT’s technical documentation, clinical evaluation and quality management system. Together with SMT’s existing ISO 13485 quality management system and MDSAP certifications, the EU MDR certification confirms that Supraflex Cruz has successfully undergone assessment against the EU MDR’s stringent requirements for safety, performance and clinical evidence. Supraflex Cruz is a sirolimus-eluting coronary stent system designed to improve luminal d
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)24.9.2026 13:00:00 CEST | Press release
-- Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect-- Narrowly missed primary endpoint of SAPS H+D (p=0.0603) with significance (nominal) on key secondary endpoint of CGI-S-ADP (p=0.0077)-- Favorable safety and tolerability profile across both doses-- Detailed results to be presented at upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference in November-- Conference call and webcast to be held today at 8:00 a.m. Eastern Time Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). For the primary endpoint of change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom